Welcome to our dedicated page for Nurexone Biologic news (Ticker: NRXBF), a resource for investors and traders seeking the latest updates and insights on Nurexone Biologic stock.
NurExone Biologic Inc. (NRXBF) news focuses on its progress as a preclinical biotechnology company developing regenerative exosome-based therapies for central nervous system injuries. The company’s updates highlight advances in its lead candidate ExoPTEN, exosome manufacturing capabilities, regulatory milestones, intellectual property, and financing activities that support its development plans.
Readers following NurExone’s news can see detailed reports on preclinical data, including dose-dependent recovery of visual function in glaucoma and optic nerve injury models and motor recovery in acute spinal cord injury models. The company also publishes laboratory analyses showing anti-inflammatory activity of its exosomes and higher biological activity compared with commercially available exosome products, which it presents as strengthening the rationale for its platform.
News releases also cover regulatory and scientific visibility, such as Orphan Drug Designation for ExoPTEN in acute spinal cord injury and invited presentations at international conferences on exosomes, regenerative medicine, and bioprocessing. These items provide insight into how NurExone is engaging with regulators and the scientific community around exosome-based therapeutics.
On the corporate side, NurExone reports on patent developments, including a U.S. Notice of Allowance and an Israeli patent grant for its exosome manufacturing process, as well as its participation in programs like ARMI’s BioFab Startup Lab. Investors can also track capital raises, warrant exercises, and private placements that fund R&D, manufacturing initiatives, and U.S. expansion through its subsidiary Exo-Top Inc., including plans for a commercial exosome production facility in Indianapolis, Indiana.
For anyone monitoring NRXBF, this news stream offers a consolidated view of scientific results, manufacturing readiness, regulatory positioning, and financial developments that shape NurExone’s trajectory in exosome-based CNS therapies.
NurExone (OTCQB: NRXBF) has called an annual general and special meeting for September 15, 2026 in Toronto to seek shareholder approval for a special resolution authorizing a share consolidation of up to 30 pre-consolidation shares for 1 post-consolidation share. If approved by at least 66⅔% of votes cast, the board would have discretion to implement the consolidation at a chosen ratio and time within 36 months, subject to TSXV acceptance and other approvals, or to decide not to proceed.
The board links the proposed consolidation to NurExone’s evaluation of potential U.S. capital markets alternatives, including a possible future listing on a major U.S. exchange, and highlights both potential benefits and liquidity risks, noting there is no assurance of any price or listing outcome.
NurExone (OTCQB: NRXBF) closed a non-brokered private placement of 1,938,326 units at C$0.55 per unit, raising gross proceeds of approximately C$1,066,078, subject to final TSX Venture Exchange acceptance. Proceeds are intended for general working capital.
Each unit includes one common share and one warrant. Each warrant allows purchase of one share at C$0.69 for 36 months, with an acceleration feature if the 20-day VWAP reaches C$1.38. All securities are subject to a hold period until December 21, 2026. NurExone develops exosome-based regenerative therapies, led by its preclinical candidate ExoPTEN for acute spinal cord and optic nerve damage.
NurExone (OTCQB: NRXBF) reported new preclinical tissue-analysis data for its exosome-based candidate ExoPTEN in an acute spinal cord injury animal model. Using spinal cord tissue from a prior efficacy study, researchers found significantly higher numbers of Myelin Basic Protein (MBP)-positive cells in ExoPTEN-treated animals versus controls two months after injury.
The increase in MBP-positive cells, a marker of myelin, was statistically significant in both rostral (p=0.01) and caudal (p=0.04) regions, adding biological support for ExoPTEN’s potential neuroprotective effect and previously reported functional recovery. NurExone also announced a conditional, cash-paid investor awareness agreement with BullVestor for Austria, Germany and Switzerland, including a C$2,500 monthly program and optional campaigns up to C$480,000, subject to TSXV acceptance.
NurExone (OTCQB: NRXBF) announced that its U.S. subsidiary Exo-Top has signed a binding MOU with Made Scientific to create an exclusive U.S. GMP manufacturing and commercial exosome supply partnership. Made Scientific operates a 60,000-square-foot, U.S. FDA and EU GMP Annex 1 compliant facility in Princeton, New Jersey.
The parties intend to start technology transfer immediately and target first GMP exosome batches in H1 2027, supporting NurExone’s clinical pipeline and planned commercial production, including lead candidate ExoPTEN. The MOU contemplates a definitive agreement with an initial five-year term and options for additional five-year renewals, and will terminate automatically if no definitive agreement is executed within six months. NurExone also disclosed that Exo-Top and BioXtek mutually agreed not to proceed with their earlier non-binding LOI, aligning U.S. GMP exosome manufacturing under the proposed Made Scientific collaboration.
NurExone (OTCQB: NRXBF) announced a bioprocess optimization initiative with Austria-based Novasign to support manufacturing infrastructure for its exosome-based therapeutic pipeline and commercial activities. Novasign’s bioprocess modeling platform, Novasign Studio, will be applied to NurExone’s proprietary exosome production process to analyze upstream bioprocess data against predefined KPIs such as process efficiency and operating costs.
The project is intended to enhance process understanding, inform a planned technology transfer to NurExone’s U.S. subsidiary Exo-Top, and identify opportunities to improve manufacturing efficiency and product consistency. According to NurExone, this work supports the company’s 2026 focus on commercial and clinical readiness for its lead candidate ExoPTEN, which has shown strong preclinical data in acute spinal cord and optic nerve damage and is advancing toward U.S. and European clinical trials under Orphan Drug Designation.
NurExone (TSXV: NRX, OTCQB: NRXBF, FSE: J90) has appointed David Stolick to its Board of Directors effective July 28, 2026, succeeding the late James “Jay” Richardson. Stolick brings finance, capital markets, M&A and healthcare leadership experience from roles at V-Wave, Exalenz Bioscience, BrainStorm Cell Therapeutics and M-Systems.
The company also entered an investor awareness engagement with Cashu Technologies running to no later than December 31, 2026. Cashu will receive US$2,500 per month and may earn an optional US$20,000–US$40,000 one-time fee, payable only in cash, subject to TSX Venture Exchange acceptance.
NurExone (OTCQB: NRXBF) closed a non-brokered private placement of 1,012,573 units at C$0.62 per unit, raising about C$627,795 in gross proceeds, subject to TSXV approval.
Each unit includes one share and one warrant at C$0.78, exercisable for 36 months, with an acceleration feature.
NurExone (OTCQB: NRXBF) announced that its U.S. subsidiary Exo-Top signed a binding MOU with ExoLyra for exclusive distribution of naïve MSC-derived exosome products in Mexico and potential expansion to Brazil and Panama.
Terms include up to 10-year exclusivity, US$180,000 upfront fees, US$800,000 funded launch, annual maintenance fees, and escalating minimum purchase commitments up to 70,000 units per year.
NurExone (OTCQB: NRXBF) reported Q1 2026 results and corporate milestones. Net loss was US$1.77 million, with R&D expenses of US$0.63 million and G&A of US$1.13 million.
The company raised about US$642 thousand via a private placement, advanced CMC readiness with positive proteomic data, executed a U.S.-focused sublicense, and reported new Australian and Korean IP protection for its exosome platform and ExoPTEN candidate.
NurExone (OTCQB: NRXBF) received a South Korean Notice of Patent Grant covering ExoPTEN, its lead exosome-based therapy candidate. The patent protects use of exosomes to deliver PTEN-targeted cargo for nerve injury treatment.
This grant adds to ExoPTEN patents in the US, Japan, Israel and Russia, alongside pending applications in the EU, China and other regions, and complements broader patents on extracellular vesicle production technologies.